<SEC-DOCUMENT>0001070081-23-000063.txt : 20231026
<SEC-HEADER>0001070081-23-000063.hdr.sgml : 20231026
<ACCEPTANCE-DATETIME>20231026160707
ACCESSION NUMBER:		0001070081-23-000063
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20231026
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20231026
DATE AS OF CHANGE:		20231026

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PTC THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001070081
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				043416587
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35969
		FILM NUMBER:		231350205

	BUSINESS ADDRESS:	
		STREET 1:		100 CORPORATE COURT
		CITY:			SOUTH PLAINFIELD
		STATE:			NJ
		ZIP:			07080-2449
		BUSINESS PHONE:		9082227000

	MAIL ADDRESS:	
		STREET 1:		100 CORPORATE COURT
		CITY:			SOUTH PLAINFIELD
		STATE:			NJ
		ZIP:			07080-2449

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PTC THERAPEUTICS INC
		DATE OF NAME CHANGE:	19980909
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tmb-20231026x8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.4.0.13 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 10/26/2023 6:43:21 PM -->
      <!-- iXBRL Library version: 1.0.8630.22539 -->
      <!-- iXBRL Service Job ID: cf4f5a10-c18d-4fea-a65d-afefa3c84243 -->

  <html xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ptct="http://www.ptcbio.com/20231026" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_10_26_2023_To_10_26_2023_2yJdvp81J0OjbGCUbLFEAw" name="dei:EntityCentralIndexKey" id="Tc_KP05cjoOVkyYyoE5KF4vbQ_2_1">0001070081</ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_26_2023_To_10_26_2023_2yJdvp81J0OjbGCUbLFEAw" name="dei:AmendmentFlag" id="Tc_vbsKhtgjR0y--WppNEhE4w_3_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="tmb-20231026.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_10_26_2023_To_10_26_2023_2yJdvp81J0OjbGCUbLFEAw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-26</xbrli:startDate><xbrli:endDate>2023-10-26</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:2pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_3fc39a1a_887a_483a_8c79_81c09bc11603"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:17pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:17pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">WASHINGTON, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:17pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_10_26_2023_To_10_26_2023_2yJdvp81J0OjbGCUbLFEAw" name="dei:DocumentType" id="Narr_-SxE-9UGUUy7Zxt9T261Hw"><b style="font-weight:bold;">8-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">CURRENT REPORT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Pursuant to Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;white-space:pre-wrap;">Date of Report (Date of earliest event reported):  </span><ix:nonNumeric contextRef="Duration_10_26_2023_To_10_26_2023_2yJdvp81J0OjbGCUbLFEAw" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="Narr_t-5aQ89JD0q_TyrO4khDKw"><b style="font-size:9pt;font-weight:bold;">October 26, 2023</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:17pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_26_2023_To_10_26_2023_2yJdvp81J0OjbGCUbLFEAw" name="dei:EntityRegistrantName" id="Narr_o-MDQ2SyQ0GPXmQeUHeDPA"><b style="font-weight:bold;">PTC THERAPEUTICS, INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Exact Name of Company as Specified in Charter)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_55447ebd_8ac3_48f2_9214_a2803b87ebd3"></a><a id="Tc_f4pvnefkAU6yXlGCgwVEIA_2_0"></a><a id="Tc_z4M4bPrreEWWUDILo8popw_2_2"></a><a id="Tc_4z0y-ZXQg06_xOZvE8cNMw_2_4"></a><a id="Tc_ue7oB9jXiEKn3wxU8urSlQ_3_0"></a><a id="Tc_9WMYqrJOK0Wxm2ExAo_-9A_3_2"></a><a id="Tc_D1Vry7M3ZkCNuYyD8i145A_3_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:31.75%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:31.75%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_26_2023_To_10_26_2023_2yJdvp81J0OjbGCUbLFEAw" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Tc_bSR-dqPHfkGMHlJoE65Ibg_1_0"><b style="font-size:9pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_26_2023_To_10_26_2023_2yJdvp81J0OjbGCUbLFEAw" name="dei:EntityFileNumber" id="Tc_WTsaJu0SwE6jFdxZEW5VdQ_1_2"><b style="font-size:9pt;font-weight:bold;">001-35969</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_26_2023_To_10_26_2023_2yJdvp81J0OjbGCUbLFEAw" name="dei:EntityTaxIdentificationNumber" id="Tc_WjF8EEsdkUKUBSipZxZu4w_1_4"><b style="font-size:9pt;font-weight:bold;">04-3416587</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:31.75%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(State or Other Jurisdiction</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Commission</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(IRS Employer</p></td></tr><tr><td style="vertical-align:bottom;width:31.75%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">of Incorporation)</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">File Number)</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Identification No.)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><a id="_c0dd52bc_18a5_4ddb_b41a_c697e874a0ff"></a><a id="Tc_i__hTGcEsU2Ny7U_tPJLvQ_2_0"></a><a id="Tc_C4IkIfIh00CHTeHRaq1vAw_3_0"></a><a id="Tc_DzO5uz0n_UebyoI7EOPuOA_3_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:48.53%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_26_2023_To_10_26_2023_2yJdvp81J0OjbGCUbLFEAw" name="dei:EntityAddressAddressLine1" id="Tc_RGrozwMp80iCuinKVVsfUg_1_0"><b style="font-size:9pt;font-weight:bold;">100 Corporate Court</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:48.53%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_26_2023_To_10_26_2023_2yJdvp81J0OjbGCUbLFEAw" name="dei:EntityAddressCityOrTown" id="Narr_aSAv8E_r5EqxbUDnXx4FJg"><b style="font-size:9pt;font-weight:bold;">South Plainfield</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_10_26_2023_To_10_26_2023_2yJdvp81J0OjbGCUbLFEAw" name="dei:EntityAddressStateOrProvince" id="Narr_6iEoN0zZ3ke-_0qf994ePQ"><b style="font-size:9pt;font-weight:bold;">NJ</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.53%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_26_2023_To_10_26_2023_2yJdvp81J0OjbGCUbLFEAw" name="dei:EntityAddressPostalZipCode" id="Tc_4v25_a1Hn0yax-Y2Fk_M3w_2_2"><b style="font-size:9pt;font-weight:bold;">07080</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Address of Principal Executive Offices)</p></td><td style="vertical-align:bottom;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.53%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Zip Code)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;">Registrant&#8217;s telephone number, including area code: </span><b style="font-size:9pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_10_26_2023_To_10_26_2023_2yJdvp81J0OjbGCUbLFEAw" name="dei:CityAreaCode" id="Narr_PpsjSpTOPEmctr7Ua06h7g"><b style="font-size:9pt;font-weight:bold;">908</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_10_26_2023_To_10_26_2023_2yJdvp81J0OjbGCUbLFEAw" name="dei:LocalPhoneNumber" id="Narr_wKFzzeGfk02FicjOkKQeGQ"><b style="font-size:9pt;font-weight:bold;">222-7000</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Not applicable</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Former Name or Former Address, if Changed Since Last Report)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:36pt;margin:0pt;">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<i style="font-style:italic;">see</i> General Instruction A.2. below):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:21.6pt;"><ix:nonNumeric contextRef="Duration_10_26_2023_To_10_26_2023_2yJdvp81J0OjbGCUbLFEAw" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Narr_soDey6pZfESKf_yi7Zwn0Q"><span style="font-family:'Segoe UI Symbol';font-size:9pt;font-style:normal;font-weight:normal;">&#9744;</span></ix:nonNumeric></span><span style="font-size:9pt;">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:21.6pt;"><ix:nonNumeric contextRef="Duration_10_26_2023_To_10_26_2023_2yJdvp81J0OjbGCUbLFEAw" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Narr_aOBZtmrApEOK4MDCA5azhQ"><span style="font-family:'Segoe UI Symbol';font-size:9pt;font-style:normal;font-weight:normal;">&#9744;</span></ix:nonNumeric></span><span style="font-size:9pt;">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:21.6pt;"><ix:nonNumeric contextRef="Duration_10_26_2023_To_10_26_2023_2yJdvp81J0OjbGCUbLFEAw" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Narr_1ZeaLf1IbU-yKLA7LEXyZA"><span style="font-family:'Segoe UI Symbol';font-size:9pt;font-style:normal;font-weight:normal;">&#9744;</span></ix:nonNumeric></span><span style="font-size:9pt;">Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:21.6pt;"><ix:nonNumeric contextRef="Duration_10_26_2023_To_10_26_2023_2yJdvp81J0OjbGCUbLFEAw" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Narr_4c2WanazakuD4wJK5J0_WQ"><span style="font-family:'Segoe UI Symbol';font-size:9pt;font-style:normal;font-weight:normal;">&#9744;</span></ix:nonNumeric></span><span style="font-size:9pt;">Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_78f9e492_9551_4dcc_bd52_e93e8cab4c26"></a><a id="Tc_NKv2BCN2iEeIebcHoAbNcw_1_0"></a><a id="Tc_3fyTXJcVKUeV2U9BgE_Btw_1_2"></a><a id="Tc_kQS7c8KW00ygcquKObMu1A_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:37.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:19.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:37.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:37.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:19.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading Symbol(s)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:37.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name of each exchange on which registered</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.99%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_26_2023_To_10_26_2023_2yJdvp81J0OjbGCUbLFEAw" name="dei:Security12bTitle" id="Tc_xG7LwhuYiUGLTTM2VlcDNw_2_0"><span style="font-size:9pt;">Common Stock, $0.001 par value per share</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:19.99%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_26_2023_To_10_26_2023_2yJdvp81J0OjbGCUbLFEAw" name="dei:TradingSymbol" id="Tc_iofXnmDMvk2DbcCKHnwcAw_2_2"><span style="font-size:9pt;">PTCT</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:37.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_26_2023_To_10_26_2023_2yJdvp81J0OjbGCUbLFEAw" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Tc_4QomnRVZbUSEWlMFUPouvw_2_4"><span style="font-size:9pt;">Nasdaq Global Select Market</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;">Emerging growth company </span><ix:nonNumeric contextRef="Duration_10_26_2023_To_10_26_2023_2yJdvp81J0OjbGCUbLFEAw" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_z2sBRsDzLUC9pp-DioA6pQ"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_31e31ab9_c5c4_4b77_bd3f_4465e28b6b3c"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Item 2.02. Results of Operations and Financial Condition</b><b style="color:#211d1e;font-weight:bold;">.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">On October 26, 2023, PTC Therapeutics, Inc. (the &#8220;Company&#8221;) announced its financial results for the quarter ended September 30, 2023. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this &quot;Report&quot;) and is incorporated by reference into this Item 2.02.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_d302d167_1063_4403_a40b_8d5d10d227b7"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 7.01. Regulation FD Disclsoure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">The Company will host a conference call on October 26, 2023 at 4:30 PM eastern time, as previously announced. During this call the Company expects to review financial results for the quarter ended September 30, 2023, as well as other corporate highlights and updates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">Directions on how to access the conference call are included in the press release furnished as Exhibit 99.1 hereto.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The information in this Report (including Items 2.02 and 7.01 and Exhibit 99.1) shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. All website addresses given in this Report or incorporated herein by reference are for information only and are not intended to be an active link or to incorporate any website information into this Report.</p><a id="_48095604_0281_4f13_826d_d5402f0cd453"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;9.01.&#160;Financial Statements and Exhibits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(d)&#160;Exhibits</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:82.93%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;No.</b></p></td><td style="vertical-align:bottom;width:2.06%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:82.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td></tr><tr><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">99.1</p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.93%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="tmb-20231026xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Press Release, dated October 26, 2023 issued by PTC Therapeutics, Inc.</span></a></p></td></tr><tr><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">104</p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.93%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The cover page from this Current Report on Form 8-K, formatted in Inline XBRL</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_7a9a790c_ca0a_427d_8646_fdd7e62f3db0"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Signature</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:44.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PTC Therapeutics,&#160;Inc.</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: October 26, 2023</p></td><td style="vertical-align:bottom;width:5.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:44.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Pierre Gravier</p></td></tr><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Pierre Gravier</p></td></tr><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tmb-20231026xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.4.105.0--><!--Created on: 10/26/2023 06:43:21 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">EXHIBIT 99.1</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">PTC Therapeutics Provides Corporate Update and </b><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;</font><font style="font-size:11pt;"><br></font><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Reports Third Quarter Financial Results</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;</font><font style="font-size:11pt;"><br></font><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">&#8211; Third quarter 2023 total revenues of $197 million and remain on target for 2023 revenue guidance &#8211;</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 0pt 36pt;"><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">&#8211; PTC strengthened its financial position following recent restructuring initiatives and Royalty Pharma transaction &#8211;</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:center;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">&#8211; PTC provides regulatory updates for pipeline programs &#8211; </i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">SOUTH PLAINFIELD, N.J., October 26, 2023</b><font style="font-family:'Arial','Helvetica','sans-serif';"> &#8211; PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the third quarter ending September 30, 2023.&#160;&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#8220;I am very proud of the progress all of our teams made this quarter,&#8221; said Matthew Klein, M.D., Chief Executive Officer, PTC Therapeutics, Inc. &#8220;</font><font style="font-family:'Arial','Helvetica','sans-serif';">The recent Royalty Pharma transaction and restructuring initiatives that we implemented have put the company on a strong financial footing. We believe we are well positioned to deliver on our most promising opportunities for growth, including the potential sepiapterin revenue opportunity of more than $1 billion and the PTC518 HD program.&#8221;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Key Corporate Updates:</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Finalized strategic partnership transaction with Royalty Pharma, in which Royalty Pharma acquired additional royalties of Evrysdi for $1.0 billion upfront. The agreement included options for PTC to sell the remainder of its royalties of Evrysdi for up to $500 million or for Royalty Pharma to acquire half of such retained royalties for up to $250 million at a later date, less royalties received by PTC. PTC maintains all economics associated with up to $250 million in the remaining commercial sales milestones associated with Evrysdi global net sales.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Third quarter 2023 revenue for the DMD franchise was $136 million, supporting increasing 2023 DMD franchise revenue guidance to between $565 million and $595 million.</font></td></tr></table><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-left:22.5pt;margin-top:0pt;padding-left:18pt;text-indent:-18pt;"><font style="display:inline-block;font-family:'Courier New';font-size:10pt;min-width:18pt;text-indent:0pt;white-space:nowrap;">o</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">Translarna&#8482; (ataluren) quarterly net product revenue was $69 million, with</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;"> new patients in existing geographies and continued geographic expansion.</font></div><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-left:22.5pt;margin-top:0pt;padding-left:18pt;text-indent:-18pt;"><font style="display:inline-block;font-family:'Courier New';font-size:10pt;min-width:18pt;text-indent:0pt;white-space:nowrap;">o</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">Emflaza</font><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;vertical-align:top;">&#174;</sup><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;"> (deflazacort) quarterly net product revenue was $67 million, with </font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">new patient starts and high compliance. </font></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Key Clinical and Regulatory Updates:</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">For Translarna, following the negative opinion from the CHMP, the CHMP gave PTC the option to request re-examination of both opinions or only one opinion. PTC decided to pursue re-examination of the negative opinion on renewal of the conditional authorization only. In accordance with EMA guidelines, PTC expects the opinion from the re-examination procedure in late January 2024, with ratification of that opinion by the European Commission 67 days later.&#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">For the United States, a type C meeting with the FDA for Translarna is scheduled for the fourth quarter of 2023.</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">PTC held a pre-NDA meeting in the third quarter with the FDA for sepiapterin in PKU to discuss the NDA submission. At the meeting, the FDA stated that the sepiapterin clinical safety and efficacy data supported NDA submission for the treatment of pediatric and adult PKU patients. It was requested that PTC complete an additional 26-week nonclinical mouse study to assess sepiapterin carcinogenicity potential prior to NDA submission. This nonclinical study was not initially required when sepiapterin was acquired from Censa, as the NDA submission was planned under the Section </font></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">505(b)(2) pathway. With PTC&#8217;s decision to file under the Section 505(b)(1) pathway, the 26-week study is considered a required NDA component needed to inform labeling and is typically completed prior to submission. PTC will continue to discuss with the FDA the potential to submit the mouse study results during the NDA review process. PTC now expects the NDA submission to occur no later than the third quarter of 2024; the submission could be submitted during the second quarter of 2024 if the nonclinical study report can be submitted during the review process.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">PTC expects to submit an MAA to the EMA for sepiapterin for the treatment of PKU in the first half of 2024. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Enrollment in the PIVOT-HD study for PTC518 for Huntington&#8217;s disease continues outside of the US for both the stage 2 and early stage 3 cohorts. PTC expects the next data update to occur in the first half of 2024. This update will include 12-month data on the initial group of subjects for which data was reported in June of this year.&#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">PTC had a type A meeting with the FDA to discuss the clinical safety data needed to enable enrollment of the PIVOT-HD trial at US study sites. At the meeting, the FDA stated that the existing three months of safety data could support 12-week dosing at 5mg and 10mg dose levels and that six months of clinical safety data demonstrating a similar favorable safety profile could support 12-month dosing in PIVOT-HD. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">PTC had a type C written-response-only meeting with FDA for vatiquinone for Friedreich ataxia to determine whether the data from the MOVE-FA study would be sufficient to support an NDA for accelerated approval. In their written response, the FDA stated that while they see the value of upright stability as a clinically meaningful endpoint, they believed a confirmatory study would likely be needed to support NDA submission. PTC has requested a follow-up live meeting to address the issues raised by the FDA. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">PTC is participating in a scientific advice procedure with the EMA to determine if the MOVE-FA data could support a conditional marketing authorization application in the EEA. PTC expects to have the outcome of this procedure in the first quarter of 2024.&#160;&#160;&#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">PTC had an informal meeting with the FDA for Upstaza for AADC deficiency. The FDA stated that the data PTC has provided to support comparability between the clinical drug product and the intended commercial drug product were still not sufficient. The FDA did say that the available data from the ongoing clinical study in the US assessing the safety of the drug delivery cannula could be used to support a BLA for accelerated approval based on biomarker data demonstrating a treatment-related increase in </font><i style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:normal;">de novo</i><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> dopamine production. The FDA suggested that PTC conduct a pre-BLA meeting prior to BLA submission to review BLA contents. This meeting has been scheduled for December 2023, and pending the outcome, PTC expects to submit the BLA shortly thereafter.&#160;</font></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Third Quarter 2023 Financial Highlights:</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Total revenues were $196.6 million for the third quarter of 2023, compared to $217.1 million for the third quarter of 2022.&#160;&#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Total revenues include net product revenue across the commercial portfolio of $144.0 million for the third quarter of 2023, compared to $134.2 million for the third quarter of 2022. Total revenues also include collaboration, royalty and manufacturing revenue of $52.5 million in the third quarter of 2023, compared to $82.9 million for the third quarter of 2022.&#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Translarna net product revenue was $69.0 million for the third quarter of 2023, compared to $76.6 million for the third quarter of 2022. These results were due to </font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">new patients in existing geographies and continued geographic expansion, while the quarter over quarter decrease was due to </font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing of bulk government orders.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Emflaza net product revenue was $67.4 million for the third quarter of 2023, compared to $54.8 million for the third quarter of 2022. These results reflect new patient starts and high compliance.&#160;</font></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Roche reported Evrysdi 2023 year-to-date sales of approximately CHF 1,065 million, resulting in royalty revenue of $50.2 million to PTC for the third quarter of 2023, as compared to $32.9 million for the third quarter of 2022.&#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Based on U.S. GAAP (Generally Accepted Accounting Principles), GAAP R&amp;D expenses were $164.2 million for the third quarter of 2023, compared to $165.5 million for the third quarter of 2022. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Non-GAAP R&amp;D expenses were $150.2 million for the third quarter of 2023, excluding $14.0 million in non-cash, stock-based compensation expense, compared to $150.4 million for the third quarter of 2022, excluding $15.1 million in non-cash, stock-based compensation expense.&#160;&#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">GAAP SG&amp;A expenses were $80.9 million for the third quarter of 2023, compared to $80.1 million for the third quarter of 2022.</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">&#160;&#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Non-GAAP SG&amp;A expenses were $67.9 million for the third quarter of 2023, excluding $13.0 million in non-cash, stock-based compensation expense, compared to $66.5 million for the third quarter of 2022, excluding $13.6 million in non-cash, stock-based compensation expense.&#160;&#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">During the third quarter of 2023, PTC incurred additional reductions in workforce as part of the continued strategic portfolio prioritization, which resulted in a one-time charge of approximately $22.6 million recorded to R&amp;D and SG&amp;A expense.&#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">The change in the fair value of deferred and contingent consideration was a loss of $1.5 million for the third quarter of 2023, compared to a gain of $5.3 million for the third quarter of 2022.&#160;&#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">The net loss was $133.0 million for the third quarter of 2023, compared to a net loss of $109.3 million for the third quarter of 2022.&#160;&#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Cash, cash equivalents, and marketable securities was $294.8 million on September 30, 2023, compared to $410.7 million at December 31, 2022.&#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Shares issued and outstanding as of September 30, 2023, were 75,459,022.&#160;</font></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0pt 18pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">PTC Updates Full Year 2023 Financial Guidance as Follows: </b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">PTC anticipates total revenues for full-year 2023 to be between $940 million and $1.0 billion. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">PTC anticipates net product revenue for the DMD franchise for full-year 2023 to be between $565 million and $595 million. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">PTC anticipates GAAP R&amp;D and SG&amp;A expenses for full-year 2023 to be between $915 million and $965 million. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">PTC anticipates Non-GAAP R&amp;D and SG&amp;A expenses for full year 2023 to be between $810 million and $860 million, excluding estimated non-cash stock-based compensation expense of $105 million. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">PTC expects to incur $37 million of one-time expenses related to the achievement of clinical success-based milestones from previous acquisitions and expenses associated with a rights exchange agreement, which have already been paid in equity and cash. </font></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0pt 18pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;line-height:1.27;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Non-GAAP Financial Measures:</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">In this press release, the financial results of PTC are provided in accordance with GAAP and using certain non-GAAP financial measures. In particular, the non-GAAP R&amp;D and SG&amp;A expense financial measures exclude non-cash, stock-based compensation expense. These non-GAAP financial measures are provided as a complement to financial measures reported in GAAP because management uses these non-GAAP financial measures when assessing and identifying operational trends. In management&#39;s opinion, these non-GAAP financial measures are useful to investors and other users of PTC&#39;s financial statements by providing greater transparency into the historical and projected operating performance of PTC and the company&#39;s future outlook. Non-GAAP financial measures are not an alternative for financial measures prepared in accordance with GAAP. Quantitative reconciliations of the non-GAAP financial measures to their respective closest equivalent GAAP financial measures are included in the table below.</font><font style="color:#666666;font-family:'Segoe UI';background:#ffffff;">&#160;</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">&#160;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt 146.25pt 0pt 133.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">PTC Therapeutics, Inc.</b><font style="font-family:'Times New Roman','Times','serif';">&#160;</font><font style="font-family:'Times New Roman','Times','serif';"><br></font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Consolidated Statements of Operations</b><font style="font-family:'Times New Roman','Times','serif';">&#160;</font><font style="font-family:'Times New Roman','Times','serif';"><br></font><font style="font-family:'Times New Roman','Times','serif';">(In thousands, except share and per share data)&#160;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:15pt;"><td style="vertical-align:middle;width:53.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:9.89%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;">&#160;</p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:53.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="5" style="vertical-align:middle;width:23.81%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;font-weight:bold;">Three Months Ended September 30,&#8239;</b><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;</font></p></td><td style="vertical-align:bottom;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="5" style="vertical-align:middle;width:21.45%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;font-weight:bold;">Nine Months Ended September 30,</b><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:53.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.53%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;font-weight:bold;">2023</b><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;</font></p></td><td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.63%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;font-weight:bold;">2022</b><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;</font></p></td><td style="vertical-align:bottom;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:9.54%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;font-weight:bold;">2023</b><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;</font></p></td><td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:11.26%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;font-weight:bold;">2022</b><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:53.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Revenues:&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td style="vertical-align:bottom;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:53.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Net product revenue&#160;</font></p></td><td style="vertical-align:middle;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;144,038&#160;</font></p></td><td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td style="vertical-align:middle;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;134,186&#160;</font></p></td><td style="vertical-align:middle;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td style="vertical-align:middle;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;506,187&#160;</font></p></td><td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td style="vertical-align:middle;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:9.89%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;407,720&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:53.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Collaboration revenue&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;-&#160;</font></p></td><td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;50,017&#160;</font></p></td><td style="vertical-align:middle;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;6&#160;</font></p></td><td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;50,024&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:53.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Royalty revenue&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;50,173&#160;</font></p></td><td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;32,924&#160;</font></p></td><td style="vertical-align:middle;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;117,857&#160;</font></p></td><td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;73,645&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:53.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Manufacturing revenue&#160;</font></p></td><td style="vertical-align:middle;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td style="vertical-align:middle;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;2,365&#160;</font></p></td><td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td style="vertical-align:middle;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td style="vertical-align:middle;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;-&#160;</font></p></td><td style="vertical-align:middle;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td style="vertical-align:middle;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td style="vertical-align:middle;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;6,716&#160;</font></p></td><td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;-&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:53.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Total revenues&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;196,576&#160;</font></p></td><td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;217,127&#160;</font></p></td><td style="vertical-align:middle;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:9.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;630,766&#160;</font></p></td><td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;531,389&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:53.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Operating expenses:&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td style="vertical-align:middle;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:53.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Cost of product sales, excluding amortization of acquired intangible assets&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;9,493&#160;</font></p></td><td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;14,011&#160;</font></p></td><td style="vertical-align:middle;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;36,368&#160;</font></p></td><td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;33,785&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:53.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Amortization of acquired intangible asset&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;58,649&#160;</font></p></td><td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;31,023&#160;</font></p></td><td style="vertical-align:middle;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;145,461&#160;</font></p></td><td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;80,790&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:53.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Research and development (1)&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;164,212&#160;</font></p></td><td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;165,462&#160;</font></p></td><td style="vertical-align:middle;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;545,210&#160;</font></p></td><td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;462,802&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:53.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Selling, general and administrative (2)&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;80,886&#160;</font></p></td><td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;80,118&#160;</font></p></td><td style="vertical-align:middle;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;256,249&#160;</font></p></td><td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;233,280&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:53.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Change in the fair value of deferred and contingent consideration&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;1,500&#160;</font></p></td><td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;(5,300)&#160;</font></p></td><td style="vertical-align:middle;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;(125,000)&#160;</font></p></td><td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;(32,200)&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:53.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Intangible asset impairment&#160;&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;-&#160;</font></p></td><td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;-&#160;</font></p></td><td style="vertical-align:middle;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:9.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;217,800&#160;</font></p></td><td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;-&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:53.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Total operating expenses&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;314,740&#160;</font></p></td><td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;285,314&#160;</font></p></td><td style="vertical-align:middle;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:9.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;1,076,088&#160;</font></p></td><td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;778,457&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:53.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Loss from operations&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;(118,164)&#160;</font></p></td><td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;(68,187)&#160;</font></p></td><td style="vertical-align:middle;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;(445,322)&#160;</font></p></td><td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;(247,068)&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:53.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Interest expense, net&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;(28,160)&#160;</font></p></td><td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;(20,880)&#160;</font></p></td><td style="vertical-align:middle;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;(84,905)&#160;</font></p></td><td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;(66,371)&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:53.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Other expense, net&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;(20,266)&#160;</font></p></td><td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;(38,141)&#160;</font></p></td><td style="vertical-align:middle;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:9.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;(8,832)&#160;</font></p></td><td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;(84,355)&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:53.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Loss before income tax benefit&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;(166,590)&#160;</font></p></td><td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;(127,208)&#160;</font></p></td><td style="vertical-align:middle;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;(539,059)&#160;</font></p></td><td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;(397,794)&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:53.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Income tax benefit&#160;&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;33,620&#160;</font></p></td><td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;17,893&#160;</font></p></td><td style="vertical-align:middle;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:9.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;68,247&#160;</font></p></td><td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;9,666&#160;</font></p></td></tr><tr style="height:21pt;"><td style="vertical-align:middle;width:53.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Net loss attributable to common stockholders&#160;</font></p></td><td style="vertical-align:middle;width:1.36%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:11.16%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;(132,970)&#160;</font></p></td><td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td style="vertical-align:middle;width:1.36%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:9.26%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;(109,315)&#160;</font></p></td><td style="vertical-align:middle;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td style="vertical-align:middle;width:1.36%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:8.17%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">(470,812)&#160;</font></p></td><td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td style="vertical-align:middle;width:1.36%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:9.89%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;(388,128)&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:53.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Weighted-average shares outstanding:&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.53%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:11.26%;margin:0pt;padding:0pt;"></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:53.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Basic and diluted (in shares)&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.53%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">75,377,997&#160;</font></p></td><td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.63%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;71,654,671&#160;</font></p></td><td style="vertical-align:middle;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:9.54%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">74,618,611&#160;</font></p></td><td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:11.26%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">71,415,849&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:53.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Net loss per share&#8212;basic and diluted (in dollars per share)&#160;</font></p></td><td style="vertical-align:middle;width:1.36%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:11.16%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;(1.76)&#160;</font></p></td><td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td style="vertical-align:middle;width:1.36%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:9.26%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;(1.53)&#160;</font></p></td><td style="vertical-align:middle;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td style="vertical-align:middle;width:1.36%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:8.17%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;(6.31)&#160;</font></p></td><td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td style="vertical-align:middle;width:1.36%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:9.89%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;(5.43)&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:53.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td style="vertical-align:middle;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:53.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;font-weight:bold;">(1) Research and development reconciliation</b><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td style="vertical-align:middle;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:53.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">GAAP research and development&#160;</font></p></td><td style="vertical-align:middle;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;164,212&#160;</font></p></td><td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td style="vertical-align:middle;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;165,462&#160;</font></p></td><td style="vertical-align:middle;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td style="vertical-align:middle;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">545,210&#160;</font></p></td><td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td style="vertical-align:middle;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:9.89%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;462,802&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:53.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Less: share-based compensation expense&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;13,986&#160;</font></p></td><td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;15,063&#160;</font></p></td><td style="vertical-align:middle;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:9.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;44,828&#160;</font></p></td><td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;41,896&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:53.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;font-weight:bold;">Non-GAAP research and development</b><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;</font></p></td><td style="vertical-align:middle;width:1.36%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:11.16%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;150,226&#160;</font></p></td><td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td style="vertical-align:middle;width:1.36%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:9.26%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;150,399&#160;</font></p></td><td style="vertical-align:middle;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td style="vertical-align:middle;width:1.36%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:8.17%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">500,382&#160;</font></p></td><td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td style="vertical-align:middle;width:1.36%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:9.89%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;420,906&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:53.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td style="vertical-align:middle;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:53.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;font-weight:bold;">(2) Selling, general and administrative reconciliation</b><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td style="vertical-align:middle;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:53.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">GAAP selling, general and administrative&#160;</font></p></td><td style="vertical-align:middle;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;80,886&#160;</font></p></td><td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td style="vertical-align:middle;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;80,118&#160;</font></p></td><td style="vertical-align:middle;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td style="vertical-align:middle;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">256,249&#160;</font></p></td><td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td style="vertical-align:middle;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:9.89%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;233,280&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:53.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Less: share-based compensation expense&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;12,956&#160;</font></p></td><td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;13,607&#160;</font></p></td><td style="vertical-align:middle;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:9.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;40,300&#160;</font></p></td><td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;41,093&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:53.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;font-weight:bold;">Non-GAAP selling, general and administrative&#160;</b><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;</font></p></td><td style="vertical-align:middle;width:1.36%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:11.16%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;67,930&#160;</font></p></td><td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td style="vertical-align:middle;width:1.36%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:9.26%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;66,511&#160;</font></p></td><td style="vertical-align:middle;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td style="vertical-align:middle;width:1.36%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:8.17%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">215,949&#160;</font></p></td><td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;">&#160;</font></p></td><td style="vertical-align:middle;width:1.36%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:9.89%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#160;192,187&#160;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 52.5pt 0pt 60pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">PTC Therapeutics, Inc.&#160;</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 52.5pt 0pt 60pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Summary Consolidated Balance Sheets</b><font style="font-family:'Times New Roman','Times','serif';">&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 52.5pt 0pt 60pt;"><font style="font-family:'Times New Roman','Times','serif';">(in thousands, except share data)&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100.64%;"><tr style="height:0.75pt;"><td style="vertical-align:middle;width:61.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:61.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:middle;width:18.23%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">September 30, 2023</b><font style="font-family:'Times New Roman','Times','serif';">&#160;</font></p></td><td style="vertical-align:middle;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:middle;width:17.91%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">December 31, 2022</b><font style="font-family:'Times New Roman','Times','serif';">&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:61.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Cash, cash equivalents and marketable securities&#160;</font></p></td><td style="vertical-align:middle;width:7.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:11.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#160;294,810&#160;</font></p></td><td style="vertical-align:middle;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:7.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:10.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#160;410,705&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:61.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Total Assets</b><font style="font-family:'Times New Roman','Times','serif';">&#160;</font></p></td><td style="vertical-align:middle;width:7.09%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">$</b><font style="font-family:'Times New Roman','Times','serif';">&#160;</font></p></td><td style="vertical-align:middle;width:11.14%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#160;1,259,885</b><font style="font-family:'Times New Roman','Times','serif';">&#160;</font></p></td><td style="vertical-align:middle;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:7.09%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">$</b><font style="font-family:'Times New Roman','Times','serif';">&#160;</font></p></td><td style="vertical-align:middle;width:10.82%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#160;1,705,619</b><font style="font-family:'Times New Roman','Times','serif';">&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:61.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:61.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Total debt&#160;</font></p></td><td style="vertical-align:middle;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#160;573,174&#160;</font></p></td><td style="vertical-align:middle;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#160;571,722&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:61.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Total deferred revenue&#160;</font></p></td><td style="vertical-align:bottom;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#160;1,224&#160;</font></p></td><td style="vertical-align:middle;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#160;1,351&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:61.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Total liability for sale of future royalties&#160;</font></p></td><td style="vertical-align:middle;width:7.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:11.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#160;763,318&#160;</font></p></td><td style="vertical-align:middle;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:7.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:10.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#160;757,886&#160;</font></p></td></tr><tr style="height:17.25pt;"><td style="vertical-align:middle;width:61.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Total liabilities</b><font style="font-family:'Times New Roman','Times','serif';">&#160;</font></p></td><td style="vertical-align:middle;width:7.09%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">$</b></p></td><td style="vertical-align:middle;width:11.14%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1,930,695</b></p></td><td style="vertical-align:middle;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:7.09%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">$</b><font style="font-family:'Times New Roman','Times','serif';">&#160;</font></p></td><td style="vertical-align:middle;width:10.82%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2,052,705</b><font style="font-family:'Times New Roman','Times','serif';">&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:61.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:61.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Total stockholders&#39; deficit (75,459,022 and 73,104,692 common shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively)&#160;</font></p></td><td style="vertical-align:middle;width:7.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:11.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#160;(670,810)&#160;</font></p></td><td style="vertical-align:middle;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:7.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:10.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#160;(347,086)&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:61.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Total liabilities and stockholders&#39; deficit</b><font style="font-family:'Times New Roman','Times','serif';">&#160;</font></p></td><td style="vertical-align:middle;width:7.09%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">$</b><font style="font-family:'Times New Roman','Times','serif';">&#160;</font></p></td><td style="vertical-align:middle;width:11.14%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#160;1,259,885</b><font style="font-family:'Times New Roman','Times','serif';">&#160;</font></p></td><td style="vertical-align:middle;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:7.09%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">$</b><font style="font-family:'Times New Roman','Times','serif';">&#160;</font></p></td><td style="vertical-align:middle;width:10.82%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#160;1,705,619</b><font style="font-family:'Times New Roman','Times','serif';">&#160;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">&#160;</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">&#160;</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">&#160;</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 52.5pt 0pt 60pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">PTC Therapeutics, Inc.&#160;</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 52.5pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Reconciliation of GAAP to Non-GAAP Projected Full Year 2023 R&amp;D and SG&amp;A Expense</b><font style="font-family:'Times New Roman','Times','serif';">&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 52.5pt 0pt 60pt;"><font style="font-family:'Times New Roman','Times','serif';">(In thousands)&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;white-space:nowrap;width:53.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:18.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Low End of Range</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:18.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">High End of Range</b></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:53.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Projected GAAP R&amp;D and SG&amp;A Expense</font></p></td><td style="vertical-align:middle;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">$</font></p></td><td style="vertical-align:middle;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;"> 915,000</font></p></td><td style="vertical-align:middle;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">$</font></p></td><td style="vertical-align:middle;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;"> 965,000</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:53.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Less: projected non-cash, stock-based compensation expense</font></p></td><td colspan="2" style="vertical-align:middle;width:18.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;"> 105,000</font></p></td><td style="vertical-align:middle;width:8.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:18.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;"> 105,000</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:53.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Projected non-GAAP R&amp;D and SG&amp;A expense </b></p></td><td style="vertical-align:middle;width:8.99%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">$</font></p></td><td style="vertical-align:middle;width:9.92%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;"> 810,000</font></p></td><td style="vertical-align:middle;width:8.99%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:8.99%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">$</font></p></td><td style="vertical-align:middle;width:9.92%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;"> 860,000</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">&#160;</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Segoe UI';font-size:9pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Acronyms:</b><font style="font-size:12pt;"><br></font><font style="font-family:'Arial','Helvetica','sans-serif';">BLA:&#160;Biologics License Application</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">CHF: Confoederatio Helvetica Francs (Swiss francs)</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">CHMP:&#160;Committee for Medicinal Products for Human Use</font><font style="font-size:12pt;"><br></font><font style="font-family:'Arial','Helvetica','sans-serif';">DMD: Duchenne Muscular Dystrophy</font><font style="font-size:12pt;"><br></font><font style="font-family:'Arial','Helvetica','sans-serif';">EMA: European Medicines Agency</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">FA: Friedreich Ataxia</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">FDA: U.S. Food and Drug Administration</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">GAAP: Generally Accepted Accounting Principles</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">HD: Huntington&#8217;s Disease</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">NDA: New Drug Application</font><font style="font-size:12pt;"><br></font><font style="font-family:'Arial','Helvetica','sans-serif';">PKU: Phenylketonuria</font><font style="font-size:12pt;"><br></font><font style="font-family:'Arial','Helvetica','sans-serif';">R&amp;D: Research and Development</font><font style="font-size:12pt;"><br></font><font style="font-family:'Arial','Helvetica','sans-serif';">SG&amp;A: Selling, General and Administrative</font><font style="font-size:12pt;"><br></font><font style="font-family:'Arial','Helvetica','sans-serif';">SMA: Spinal Muscular Atrophy</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">STRIDE: Strategic Targeting of Registries and International Database of Excellence</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Today&#39;s Conference Call and Webcast Reminder: </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">To access the call by phone, please </font><font style="font-family:'Arial','Helvetica','sans-serif';">click here</font><font style="font-family:'Arial','Helvetica','sans-serif';"> to register and you will be provided with dial-in details. To avoid delays, we recommend participants dial in to the conference call 15 minutes prior to the start of the call. The webcast conference call can be accessed on the Investor section of the PTC website at </font><font style="font-family:'Arial','Helvetica','sans-serif';">https://ir.ptcbio.com/events-presentations</font><font style="font-family:'Arial','Helvetica','sans-serif';">. A replay of the call will be available approximately two hours after completion of the call and will be archived on the company&#39;s website for 30 days following the call.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">About PTC Therapeutics, Inc.</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">PTC is a global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC&#39;s ability to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines and our mission to provide access to best-in-class treatments for patients who have an unmet medical need. The company&#39;s strategy is to leverage its strong scientific expertise and global commercial infrastructure to maximize value for its patients and other stakeholders. To learn more about PTC, please visit us at </font><font style="font-family:'Arial','Helvetica','sans-serif';">www.ptcbio.com</font><font style="font-family:'Arial','Helvetica','sans-serif';"> and follow us on Facebook, on Twitter at @PTCBio, and on LinkedIn.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">For More Information:</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Investors:</b><font style="font-size:11pt;"><br></font><font style="font-family:'Arial','Helvetica','sans-serif';">Kylie O&#39;Keefe</font><font style="font-size:11pt;"><br></font><font style="font-family:'Arial','Helvetica','sans-serif';">+1 (908) 300-0691</font><font style="font-size:11pt;"><br></font><font style="font-family:'Arial','Helvetica','sans-serif';">kokeefe@ptcbio.com</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Media:</b><font style="font-size:11pt;"><br></font><font style="font-family:'Arial','Helvetica','sans-serif';">Jeanine Clemente</font><font style="font-size:11pt;"><br></font><font style="font-family:'Arial','Helvetica','sans-serif';">+1 (908) 912-9406</font><font style="font-size:11pt;"><br></font><font style="font-family:'Arial','Helvetica','sans-serif';">jclemente@ptcbio.com</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Forward-Looking Statements:</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this release, other than statements of historic fact, are forward-looking statements, including the information provided under the heading &quot;PTC Updates Full Year 2023 Revenue Guidance as Follows&quot;, including with respect to (i) 2023 total revenue guidance, (ii) 2023 net product revenue guidance for the DMD franchise, (iii) 2023 GAAP and non-GAAP R&amp;D and SG&amp;A expense guidance and (iv) 2023 acquisition related one-time expense guidance, and statements regarding: the future expectations, plans and prospects for PTC, including with respect to the expected timing of clinical trials and studies, availability of data, regulatory submissions and responses, commercialization and other matters with respect to its products and product candidates; PTC&#39;s strategy, future operations, future financial position, future revenues, projected costs; the extent, timing and financial aspects of our strategic pipeline prioritization and reductions in workforce; and the objectives of management. Other forward-looking statements may be identified by the words, &quot;guidance&quot;, &quot;plan,&quot; &quot;anticipate,&quot; &quot;believe,&quot; &quot;estimate,&quot; &quot;expect,&quot; &quot;intend,&quot; &quot;may,&quot; &quot;target,&quot; &quot;potential,&quot; &quot;will,&quot; &quot;would,&quot; &quot;could,&quot; &quot;should,&quot; &quot;continue,&quot; and similar expressions.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">PTC&#39;s actual results, performance or achievements could differ materially from those expressed or implied by forward-looking statements it makes as a result of a variety of risks and uncertainties, including those related to: the outcome of pricing, coverage and reimbursement negotiations with third party payors </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">for PTC&#39;s products or product candidates that PTC commercializes or may commercialize in the future; PTC&#39;s ability to maintain its marketing authorization of Translarna for the treatment of nmDMD in Brazil, Russia, the European Economic Area (EEA) and other regions, including whether the European Medicines Agency (EMA) determines in the re-examination process of the Committee for Medicinal Products for Human Use&#8217;s negative opinion that the benefit-risk balance of Translarna authorization supports renewal of such authorization; PTC&#39;s ability to complete Study 041, which is a specific obligation to continued marketing authorization in the EEA; PTC&#39;s ability to utilize results from Study 041, a </font><font style="font-family:'Arial','Helvetica','sans-serif';">randomized, 18-month, placebo-controlled clinical trial of Translarna for the treatment of nmDMD followed by an 18-month open-label extension, to support a renewal of the conditional marketing authorization for Translarna for the treatment of nmDMD in the EEA and to support a marketing approval for Translarna for the treatment of nmDMD in the United States; whether investigators agree with PTC&#39;s interpretation of the results of clinical trials and the totality of clinical data from our trials in Translarna; expectations with respect to Upstaza, including any regulatory submissions and potential approvals, commercialization, manufacturing capabilities, the potential achievement of development, regulatory and sales milestones and contingent payments that PTC may be obligated to make; expectations with respect to the commercialization of Evrysdi under our SMA collaboration; expectations with respect to the commer</font><font style="font-family:'Arial','Helvetica','sans-serif';">cialization of Tegsedi and Waylivra; the timing of and actual expenses incurred in connection with the discontinuation of PTC&#8217;s preclinical and early research programs in gene therapy and reductions in workforce, which may be in different periods and may be materially higher than estimated; the savings that may result from the discontinuation of PTC&#8217;s strategic pipeline prioritization and reductions in workforce, which may be materially less than expected; significant business effects, including the effects of industry, market, economic, political or regulatory conditions; changes in tax and other laws, regulations, rates and policies; the eligible patient base and commercial potential of PTC&#39;s products and product candidates; PTC&#39;s scientific approach and general development progress; the potential financial impact and benefits of PTC&#8217;s leased biologics manufacturing facility; PTC&#39;s ability to satisfy its obligations under the terms of its lease agreements, including for its leased biologics manufacturing facility;</font><font style="font-family:'Arial','Helvetica','sans-serif';"> </font><font style="font-family:'Arial','Helvetica','sans-serif';">the sufficiency of PTC&#39;s cash resources and its ability to obtain adequate financing in the future for its foreseeable and unforeseeable operating expenses and capital expenditures; and the factors discussed in the &quot;Risk Factors&quot; section of PTC&#39;s most recent Quarterly Report on Form 10-Q and Annual Report on Form 10-K, as well as any updates to these risk factors filed from time to time in PTC&#39;s other filings with the SEC. You are urged to carefully consider all such factors.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that any product will receive or maintain regulatory approval in any territory, or prove to be commercially successful, including Translarna, Emflaza, Upstaza, Evrysdi, Tegsedi or Waylivra.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">The forward-looking statements contained herein represent PTC&#39;s views only as of the date of this press release and PTC does not undertake or plan to update or revise any such forward-looking statements to reflect actual results or changes in plans, prospects, assumptions, estimates or projections, or other circumstances occurring after the date of this press release except as required by law.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>tmb-20231026.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.4.0.13 -->
<!--Based on XBRL 2.1-->
<!--Created on: 10/26/2023 6:43:25 PM-->
<!--Modified on: 10/26/2023 6:43:25 PM-->
<xsd:schema targetNamespace="http://www.ptcbio.com/20231026" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:srt-roles="http://fasb.org/srt-roles/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ptct="http://www.ptcbio.com/20231026" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:cef="http://xbrl.sec.gov/cef/2023" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="tmb-20231026_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="tmb-20231026_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>tmb-20231026_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.4.0.13 -->
<!--Based on XBRL 2.1-->
<!--Created on: 10/26/2023 6:43:25 PM-->
<!--Modified on: 10/26/2023 6:43:25 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Written Communications</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Soliciting Material</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Issuer Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>tmb-20231026_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.4.0.13 -->
<!--Based on XBRL 2.1-->
<!--Created on: 10/26/2023 6:43:25 PM-->
<!--Modified on: 10/26/2023 6:43:25 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="tmb-20231026.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638339426058340490" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentType_638339426058340490" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638339426058340490" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638339426058340490" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638339426058340490" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFileNumber_638339426058340490" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638339426058340490" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityRegistrantName_638339426058340490" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638339426058340490" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638339426058340490" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638339426058350513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638339426058350513" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638339426058350513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638339426058350513" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638339426058350513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638339426058350513" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638339426058350513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638339426058350513" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638339426058350513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638339426058350513" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638339426058350513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CityAreaCode_638339426058350513" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638339426058350513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_LocalPhoneNumber_638339426058350513" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications_638339426058350513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_WrittenCommunications_638339426058350513" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial_638339426058350513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SolicitingMaterial_638339426058350513" order="14" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer_638339426058350513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_PreCommencementTenderOffer_638339426058350513" order="15" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer_638339426058350513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer_638339426058350513" order="16" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638339426058350513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_Security12bTitle_638339426058350513" order="17" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638339426058360514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_TradingSymbol_638339426058360514" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638339426058360514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SecurityExchangeName_638339426058360514" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638339426058360514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638339426058360514" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638339426058360514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638339426058360514" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638339426058360514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AmendmentFlag_638339426058360514" order="22" use="optional" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139672396027632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Oct. 26, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Oct. 26,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-35969<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PTC THERAPEUTICS, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">04-3416587<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">100 Corporate Court<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South Plainfield<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07080<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">908<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">222-7000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PTCT<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001070081<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>tmb-20231026x8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="tmb-20231026.xsd" xlink:type="simple"/>
    <context id="Duration_10_26_2023_To_10_26_2023_2yJdvp81J0OjbGCUbLFEAw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
        </entity>
        <period>
            <startDate>2023-10-26</startDate>
            <endDate>2023-10-26</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="Duration_10_26_2023_To_10_26_2023_2yJdvp81J0OjbGCUbLFEAw"
      id="Tc_KP05cjoOVkyYyoE5KF4vbQ_2_1">0001070081</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_10_26_2023_To_10_26_2023_2yJdvp81J0OjbGCUbLFEAw"
      id="Tc_vbsKhtgjR0y--WppNEhE4w_3_1">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_10_26_2023_To_10_26_2023_2yJdvp81J0OjbGCUbLFEAw"
      id="Narr_-SxE-9UGUUy7Zxt9T261Hw">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_10_26_2023_To_10_26_2023_2yJdvp81J0OjbGCUbLFEAw"
      id="Narr_t-5aQ89JD0q_TyrO4khDKw">2023-10-26</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="Duration_10_26_2023_To_10_26_2023_2yJdvp81J0OjbGCUbLFEAw"
      id="Narr_o-MDQ2SyQ0GPXmQeUHeDPA">PTC THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_10_26_2023_To_10_26_2023_2yJdvp81J0OjbGCUbLFEAw"
      id="Tc_bSR-dqPHfkGMHlJoE65Ibg_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="Duration_10_26_2023_To_10_26_2023_2yJdvp81J0OjbGCUbLFEAw"
      id="Tc_WTsaJu0SwE6jFdxZEW5VdQ_1_2">001-35969</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_10_26_2023_To_10_26_2023_2yJdvp81J0OjbGCUbLFEAw"
      id="Tc_WjF8EEsdkUKUBSipZxZu4w_1_4">04-3416587</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_10_26_2023_To_10_26_2023_2yJdvp81J0OjbGCUbLFEAw"
      id="Tc_RGrozwMp80iCuinKVVsfUg_1_0">100 Corporate Court</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_10_26_2023_To_10_26_2023_2yJdvp81J0OjbGCUbLFEAw"
      id="Narr_aSAv8E_r5EqxbUDnXx4FJg">South Plainfield</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_10_26_2023_To_10_26_2023_2yJdvp81J0OjbGCUbLFEAw"
      id="Narr_6iEoN0zZ3ke-_0qf994ePQ">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_10_26_2023_To_10_26_2023_2yJdvp81J0OjbGCUbLFEAw"
      id="Tc_4v25_a1Hn0yax-Y2Fk_M3w_2_2">07080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_10_26_2023_To_10_26_2023_2yJdvp81J0OjbGCUbLFEAw"
      id="Narr_PpsjSpTOPEmctr7Ua06h7g">908</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_10_26_2023_To_10_26_2023_2yJdvp81J0OjbGCUbLFEAw"
      id="Narr_wKFzzeGfk02FicjOkKQeGQ">222-7000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="Duration_10_26_2023_To_10_26_2023_2yJdvp81J0OjbGCUbLFEAw"
      id="Narr_soDey6pZfESKf_yi7Zwn0Q">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="Duration_10_26_2023_To_10_26_2023_2yJdvp81J0OjbGCUbLFEAw"
      id="Narr_aOBZtmrApEOK4MDCA5azhQ">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="Duration_10_26_2023_To_10_26_2023_2yJdvp81J0OjbGCUbLFEAw"
      id="Narr_1ZeaLf1IbU-yKLA7LEXyZA">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="Duration_10_26_2023_To_10_26_2023_2yJdvp81J0OjbGCUbLFEAw"
      id="Narr_4c2WanazakuD4wJK5J0_WQ">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="Duration_10_26_2023_To_10_26_2023_2yJdvp81J0OjbGCUbLFEAw"
      id="Tc_xG7LwhuYiUGLTTM2VlcDNw_2_0">Common Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_10_26_2023_To_10_26_2023_2yJdvp81J0OjbGCUbLFEAw"
      id="Tc_iofXnmDMvk2DbcCKHnwcAw_2_2">PTCT</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_10_26_2023_To_10_26_2023_2yJdvp81J0OjbGCUbLFEAw"
      id="Tc_4QomnRVZbUSEWlMFUPouvw_2_4">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_10_26_2023_To_10_26_2023_2yJdvp81J0OjbGCUbLFEAw"
      id="Narr_z2sBRsDzLUC9pp-DioA6pQ">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>8
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M4$L! A0#%     @ XX!:5YTXJ+3N    *P(  !$              ( !KP
M &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ XX!:5YE<G",0!@  G"<
M !,              ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M    " #C@%I7Q5OYMU8$  "Z$   &               @($-"   >&PO=V]R
M:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ XX!:5Y^@&_"Q @  X@P
M  T              ( !F0P  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " #C
M@%I7EXJ[',     3 @  "P              @ %U#P  7W)E;',O+G)E;'-0
M2P$"% ,4    " #C@%I7'#AEZC\!   \ @  #P              @ %>$
M>&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ XX!:5R0>FZ*M    ^ $  !H
M             ( !RA$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L!
M A0#%     @ XX!:5V60>9(9 0  SP,  !,              ( !KQ(  %M#
G;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  ^1,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="tmb-20231026x8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>tmb-20231026.xsd</File>
    <File>tmb-20231026_lab.xml</File>
    <File>tmb-20231026_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" original="tmb-20231026x8k.htm">tmb-20231026x8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tmb-20231026x8k.htm": {
   "nsprefix": "ptct",
   "nsuri": "http://www.ptcbio.com/20231026",
   "dts": {
    "schema": {
     "local": [
      "tmb-20231026.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "tmb-20231026_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "tmb-20231026_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "tmb-20231026x8k.htm"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 22
   },
   "report": {
    "R1": {
     "role": "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation",
     "longName": "00090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_10_26_2023_To_10_26_2023_2yJdvp81J0OjbGCUbLFEAw",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20231026x8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_26_2023_To_10_26_2023_2yJdvp81J0OjbGCUbLFEAw",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20231026x8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0001070081-23-000063-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001070081-23-000063-xbrl.zip
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M@ LP.U^_<L_C+\FN354?W3S8^['?=E>$G<K-'U!+ P04    " #C@%I7]'[
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MR1<:0)$*==1].V>1#N#;A[%*$>J7J6&F.F6ZGNF[UI:'1D91-5<81,-5*[Z
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M_<R.7^YHQU >OK(9W9!K9OR#;* 55\AG1CS<T8AT:7UE$T;?\;Y0ONA&#MY
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MZJ!?]AF< DAZN9!\=_MN!J9Q3]'D37*?-)*=0U:"V1DJLRDV6F*Y(9X(8\L
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MUR>5Y"(]K 48B4'$J\RS%7O%D_'BCC,<!C1Y$'G-^),YYUK:7Q6584]2?C*
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M%D]NGF&G8#5H2[RYS%T3015_F>6R0CIG*V&G=?0AQ-'[LZ3?H1Q[19KL4#_
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MG5#<-XXQ4CLS,1Z!K,FA@!<PPS?-!8:1AR.7"_2[PG1NL1?5/HXVD(E.AOH
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M!B,]C&\:=:NW4G,9C&0PTHH0M=VQNBT37#-(Z8&,TVE8[6;+(*7UZ?:9!^F
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M3N15?X_R>$.?.]?#2*:!6W&D+Z/CC%,=7_ (//!D=#+[A1Y@?6[ &6]G_-_
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MNU\_G1XK<OWJ25\./2=FGSR'X-1I&/KP#OJL]R]AR23=8$IG']X?XQV& RE
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M4V#;<,2C,7=H;O")7F]852<MR)7KQ8Z\$='$ @V08V;B'%("D0-=>W_ENSQ
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M+3(P,C,Q,#(V7W!R92YX;6Q02P$"% ,4    " #C@%I7UF2&::\6   EK0
M$P              @ '?#0  =&UB+3(P,C,Q,#(V>#AK+FAT;5!+ 0(4 Q0
M   ( .. 6E?B.K&&U#,  %BO @ 7              "  ;\D  !T;6(M,C R
F,S$P,C9X97@Y.60Q+FAT;5!+!08     !0 % $@!  #(6      !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
